Segment Information

12 Months Ended

Dec. 31, 2014

Segment Information

Segment Information

17. Segment Information

        We currently operate as one operating segment. However, our chief operating decision makers regularly review revenues, cost of product sales and gross profit data as a primary measure of performance for each of our four commercial products. We commenced sales of Orenitram during the second quarter of 2014.

        Net revenues, cost of product sales and gross profit for each of our commercial products were as follows (in thousands):

	Remodulin		Tyvaso		Adcirca		Orenitram		Total
Year Ended December 31, 2014
Net revenues	$	553,728	$	463,067	$	221,471	$	41,267	$	1,279,533
Cost of product sales		47,327		57,442		13,495		7,619		125,883
Gross profit	$	506,401	$	405,625	$	207,976	$	33,648	$	1,153,650
Year Ended December 31, 2013
Net revenues	$	491,179	$	438,793	$	176,972	$	—	$	1,106,944
Cost of product sales		59,314		60,831		10,982		—		131,127
Gross profit	$	431,865	$	377,962	$	165,990	$	—	$	975,817
Year Ended December 31, 2012
Net revenues	$	457,969	$	325,614	$	122,540	$	—	$	906,123
Cost of product sales		57,618		53,825		7,854		—	$	119,297
Gross profit	$	400,351	$	271,789	$	114,686	$	—	$	786,826

        Geographic revenues are determined based on the country in which our customers (distributors) are located. Net revenues from external customers by geographic area are as follows (in thousands):

Year Ended December 31,	2014		2013		2012
United States	$	1,180,759	$	1,032,435	$	846,611
Rest-of-World(1)		107,760		84,549		69,465
Total	$	1,288,519	$	1,116,984	$	916,076

(1) Primarily Europe.

        For the years ended December 31, 2014, 2013 and 2012, sales to Accredo Health Group, Inc. comprised 58 percent, 57 percent and 56 percent, respectively, of total consolidated net revenues.

        Long-lived assets (property, plant and equipment) located by geographic area are as follows (in thousands):

Year Ended December 31,	2014		2013		2012
United States	$	462,377	$	442,673	$	425,585
Rest-of-World(1)		16,044		22,277		28,100
Total	$	478,421	$	464,950	$	453,685

(1) Facilities principally located in the United Kingdom.